Science Translational Medicine report led by Lymphoma Research Foundation Scientific Advisory Board members and LRF Grantees As personalized medicine becomes increasingly popular, researchers continue to discover ways to ensure that the right patient receives the right treatment at the right…
The Annual Meeting of the American Society of Hematology (ASH), convened in December 2014, highlighted the expanding array of novel therapy treatments showing promise for non-Hodgkin lymphoma (NHL) patients. Covering a gamut of research from expanded analyses of recently approved…
The Annual Meeting of the American Society of Hematology (ASH), convened in December 2014, highlighted the expanding array of novel therapy treatments showing promise for non-Hodgkin lymphoma (NHL) patients. Covering a gamut of research from expanded analyses of recently approved…
The Annual Meeting of the American Society of Hematology (ASH), convened in December 2014, highlighted the expanding array of novel therapy treatments showing promise for non-Hodgkin lymphoma (NHL) patients. Covering a gamut of research from expanded analyses of recently approved…
Though much of the lymphoma research presented at the Annual Meeting of the American Society of Hematology (ASH) in December 2014 focused on the growing number of novel therapies for this disease, a subset of presentations focused on the impact…
Double hit lymphoma (DHL) describes patients whose lymphoma tumors exhibit mutations on two significant genes, where most lymphoma patients have a mutation on only one. Currently found primarily in diffuse large B-cell lymphoma (DLBCL), DHL patients often respond poorly to…